



Press Release

Human Metabolome Technologies and Agilent Technologies Collaborate on Metabolomics Solution to Speed Disease and Drug Research

**HMT's Biochemical Expertise, Agilent's Instrument Technology Combine
to Help Scientists Map Human Metabolome**

Tokyo, Japan – Jun 20, 2005 - Human Metabolome Technologies, a Japanese bioventure, and Agilent Technologies Inc. (NYSE: A) today announced they have signed an agreement to collaborate on an integrated set of metabolome analysis tools designed to help researchers discover drugs and potential therapeutics.

Under the agreement, the two companies will work to integrate HMT's novel biochemical assays with Agilent's capillary electrophoresis (CE) and mass spectrometry (MS) technologies for the profiling, identification and quantitation of metabolic markers. Metabolomics, which aims to characterize the complete set of metabolites, provides critical insights into how living things function under particular conditions, such as stress or disease, and may help identify targets for drug development. Typical human cells contain thousands of metabolites, and the aim of the HMT/Agilent solution is to develop a new and unique mass spectrometry based workflow for high throughput analysis.

"Metabolomics is a rapidly-emerging and promising area in life science research and an area of focus for Agilent," said Taia Ergueta, Agilent business manager for proteomics, Life Science and Chemical Analysis. "We offer competencies in gene expression, separation technologies, mass spectrometry and informatics. The further application of HMT's expertise in metabolomics methodologies will speed the development of new tools for metabolomics research."

The Agilent and HMT metabolomics solution is expected to be on the market within six months.

"The human metabolome is the next frontier of research beyond the genome and the proteome, and metabolomics promises exciting advances," said Dr. Yoshihiro Ohtaki, president of HMT. "The combination of Agilent's robust and sensitive CE/MS technology with our latest metabolomics methodologies will speed the identification of metabolites and improve scientists' ability to map the human metabolome."

HMT and Agilent are participating in the First International Conference of the Metabolomics Society in Tsuruoka City, Japan today through June 23.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 28,000 employees serve customers in more than 110 countries. Agilent had net revenue of \$7.2 billion in fiscal year 2004. Information about Agilent is available on the Web at www.agilent.com.

About Human Metabolome Technologies

Founded in July 2003, Human Metabolome Technologies (HMT) is an innovative metabolomics provider focusing on discovering biomarkers in drug development, diagnosis and food production. Based on its original CE-MS technology, more than 1,600 metabolites can be measured simultaneously in high-speed and high-resolution manner. HMT has already signed contracts with a number of pharmaceutical and food companies for biomarker studies. For additional information, visit humanmetabolome.com.

Contact Information:

Mineo Morohashi, Business Development
Human Metabolome Technologies, Inc.
busdev@humanmetabolome.com